Cardiovascular disease risk factors in HIV-Infected patients in the HAART era

被引:16
作者
Galli, M [1 ]
Ridolfo, AL [1 ]
Gervasoni, C [1 ]
机构
[1] Univ Milan, L Sacco Hosp, Inst Infect Dis & Trop Med, I-20157 Milan, Italy
来源
HIV-ASSOCIATED CARDIOVASCULAR DISEASE: CLINICAL AND BIOLOGICAL INSIGHTS | 2001年 / 946卷
关键词
cardiovascular disease; risk; HIV infection; metabolism; antiretroviral therapy;
D O I
10.1111/j.1749-6632.2001.tb03913.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
HIV infection is accompanied by disturbances in lipid and glucose metabolism, which are further compounded by changes induced by antiretroviral drugs. There is increasing concern that these changes will lead to an epidemic of cardiovascular disease. Cardiovascular disease will no doubt increase, but current data indicate that the average absolute levels are likely to remain low, although patients with additional risks (smoking, hypertension, diabetes, age, family history, etc.) are certainly more susceptible. The complications of therapy need to be taken into account when deciding on the time of treatment, and reducing risk factors should become a routine aspect of the care of an HIV population that now lives longer as a result of highly active antiretroviral therapy.
引用
收藏
页码:200 / 213
页数:14
相关论文
共 111 条
[1]   Lipodystrophy associated with nevirapine-containing antiretroviral therapies [J].
Aldeen, T ;
Wells, C ;
Hay, P ;
Davidson, F ;
Lau, R .
AIDS, 1999, 13 (07) :865-867
[2]  
Assmann G, 1998, EUR HEART J, V19, pA2
[3]   Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men [J].
Assmann, G ;
Schulte, H ;
vonEckardstein, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (14) :1179-1184
[4]   FDA warns of potential protease-inhibitor link to hyperglycaemia [J].
Ault, A .
LANCET, 1997, 349 (9068) :1819-1819
[5]  
Balfour JAB, 1999, DRUGS, V57, P921
[6]  
Behrens G, 1998, LANCET, V351, P1958, DOI 10.1016/S0140-6736(98)26026-0
[7]   Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors [J].
Behrens, G ;
Dejam, A ;
Schmidt, H ;
Balks, HJ ;
Brabant, G ;
Körner, T ;
Stoll, M ;
Schmidt, RE .
AIDS, 1999, 13 (10) :F63-F70
[8]   The platelet and endothelium in HIV infection [J].
Blann, A ;
Constans, J ;
Dignat-George, F ;
Seigneur, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 100 (03) :613-614
[9]  
BONNET E, 2000, 7 C RETR OPP INF SAN
[10]   Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens [J].
Bonnet, F ;
Savès, M ;
Droz, C ;
Peuchant, E ;
Chêne, G ;
Beylot, J ;
Morlat, P .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (02) :199-200